Impact Investing for Cancer Custom Case Solution & Analysis

Evidence Brief: Impact Investing for Cancer

1. Financial Metrics

• Drug Development Costs: Average cost to bring a new drug to market is estimated at 2.6 billion dollars, including the cost of failures (Exhibit 1).
• Funding Gap: A critical financing gap exists between basic research (grants of 100,000 to 500,000 dollars) and clinical trials (requiring 10 million to 50 million dollars).
• Success Rates: Only 12 percent of drugs entering Phase I clinical trials eventually receive FDA approval (Exhibit 4).
• Bridge Project Scale: Initial funding involved 1.5 million dollar grants over two years per project, shared between MIT and Dana-Farber (Paragraph 12).
• Time Horizon: The average time from initial discovery to market launch spans 10 to 15 years.

2. Operational Facts

• Institutional Collaboration: The Bridge Project links the Koch Institute (MIT) with Dana-Farber/Harvard Cancer Center (DF/HCC), combining engineering/physical sciences with clinical oncology.
• Project Selection: Teams must include one researcher from each institution. Selection is based on potential for clinical impact within a short timeframe.
• Translational Focus: The project targets the Valley of Death, specifically the transition from laboratory validation to human clinical trials.
• Intellectual Property: IP is managed through respective Technology Licensing Offices (TLOs) at MIT and Harvard.

3. Stakeholder Positions

• Tyler Jacks (Director, Koch Institute): Seeks to accelerate the pace of clinical application for MIT engineering breakthroughs.
• Edward Benz (CEO, Dana-Farber): Focuses on patient outcomes and the need for new therapeutic options in recalcitrant cancers.
• Philanthropic Donors: Traditionally provide one-way grants but increasingly seek measurable impact and potential recycling of capital.
• Venture Capitalists: Generally avoid early-stage translational research due to high technical risk and long durations before liquidity events.

4. Information Gaps

• Royalty Terms: The case does not specify the exact revenue-share agreement between the Bridge Project and the parent institutions if a discovery is commercialized.
• Historical Exit Data: Limited data on the valuation of previous spin-offs specifically originating from Bridge Project grants.
• Investor Appetite: No definitive survey of Limited Partners (LPs) regarding their willingness to accept lower-than-market returns for high social impact in oncology.

Strategic Analysis

1. Core Strategic Question

• How can the Bridge Project transform from a grant-dependent philanthropic initiative into a self-sustaining investment vehicle to bridge the 50 million dollar funding gap for Phase I trials?
• How to maintain academic freedom and collaborative research while introducing the discipline and exit-requirements of commercial capital?

2. Structural Analysis

Value Chain Analysis: The bottleneck is not in discovery (Phase 0) or late-stage commercialization (Phase III). The structural failure occurs at the transition point where NIH grants end and private equity has not yet entered. This stage requires high-risk tolerance that neither government nor traditional markets provide.

Jobs-to-be-Done: For the researcher, the job is securing path-to-clinic funding without losing control of the science. For the impact investor, the job is deploying capital that achieves patient survival metrics while preserving the principal for future reinvestment.

3. Strategic Options

Option 1: The Venture Philanthropy Fund. Transition to a model where donors contribute to a revolving fund. If a project is licensed or spun off, a portion of the proceeds returns to the fund.
Trade-offs: Increases financial sustainability but requires complex legal restructuring of IP agreements.
Resource Requirements: Dedicated investment committee and legal staff to manage equity stakes.

Option 2: Royalty Monetization. Sell future royalty streams of promising early-stage assets to institutional investors to fund current Phase I trials.
Trade-offs: Provides immediate liquidity but sacrifices long-term upside for the institutions.
Resource Requirements: Deep financial modeling expertise and access to debt markets.

Option 3: Strategic Corporate Partnerships. Form a consortium of 3-5 pharmaceutical companies that provide evergreen funding in exchange for right-of-first-refusal on Bridge Project discoveries.
Trade-offs: Guarantees exit paths but may limit the competitive bidding process for the IP.
Resource Requirements: High-level business development and negotiation capacity.

4. Preliminary Recommendation

Pursue Option 1 (Venture Philanthropy Fund). This model aligns with the mission of the Koch Institute and Dana-Farber by keeping the focus on impact while introducing a mechanism for capital recycling. It avoids the premature sale of assets (Option 2) and the potential for corporate capture of research agendas (Option 3).

Implementation Roadmap

1. Critical Path

• Month 1-2: Governance Design. Establish an Investment Committee (IC) comprising clinicians, engineers, and venture capitalists. Define the criteria for moving a project from grant-funded to equity-funded status.
• Month 3-4: IP Framework Revision. Negotiate a standardized inter-institutional agreement between MIT and Harvard TLOs to streamline licensing for Fund-backed projects.
• Month 5-6: Capital Raising. Convert existing donor relationships into Fund commitments. Target an initial 100 million dollar pilot fund to support 5-7 Phase I trials.
• Month 7+: Project Selection and Deployment. Transition the top 20 percent of current Bridge Project grant recipients into the Fund pipeline.

2. Key Constraints

• Culture Clash: The primary constraint is the friction between academic timelines and the urgency of investment cycles. Researchers may resist the clinical-focus requirements imposed by an IC.
• Regulatory Friction: FDA Phase I approval timelines are outside the control of the fund, creating unpredictable capital call schedules.

3. Risk-Adjusted Implementation Strategy

To mitigate the risk of scientific failure, the fund will utilize a milestone-based disbursement model. Capital is not deployed in a single tranche but tied to specific technical de-risking events (e.g., successful toxicology studies). If a milestone is missed, funding ceases immediately to preserve capital for other assets in the portfolio. This avoids the sunk-cost fallacy common in academic research.

Executive Review and BLUF

1. BLUF

The Bridge Project must evolve into a 100 million dollar Venture Philanthropy Fund to overcome the funding gap between laboratory discovery and clinical trials. The current grant-only model is insufficient to move high-potential therapies into Phase I/II trials where the 10 million to 50 million dollar requirement resides. By structuring a revolving fund, the institutions can recycle exit proceeds to sustain future research. Success depends on a disciplined, milestone-based investment approach that prioritizes clinical viability over pure scientific inquiry. Failure to transition will result in promising oncology breakthroughs remaining trapped in the laboratory, effectively wasting the initial philanthropic investment.

2. Dangerous Assumption

The analysis assumes that scientific excellence at MIT and Harvard correlates directly with commercial viability. In reality, a breakthrough in the lab often lacks the manufacturing scalability or the clear regulatory pathway required for a successful clinical exit. The team assumes the science is the hard part; the market and regulatory hurdles are often the actual points of failure.

3. Unaddressed Risks

• Adverse Selection (Probability: High; Consequence: Severe): The best-performing projects might bypass the internal Fund to seek higher valuations from external Venture Capital, leaving the Bridge Fund with lower-quality assets.
• Conflict of Interest (Probability: Medium; Consequence: High): Institutional participation in equity may bias clinical trial design or reporting at Dana-Farber, creating significant reputational and legal risks.

4. Unconsidered Alternative

The team did not consider a Megafund approach using securitized debt. By pooling a large number of cancer research projects (100+), the statistical probability of a few successes can back the issuance of Research Backed Obligations (RBOs). This would tap into much larger pools of institutional capital rather than relying on the limited pool of impact investors and donors.

VERDICT: APPROVED FOR LEADERSHIP REVIEW